![Breaking News: First Wave Biopharma’s AAPS 2022 PharmSci 360 Accepts Abstract for ADRULIPASE Formulation!](https://marketsgonewild.com/wp-content/uploads/2024/12/Breaking-News-First-Wave-Biopharmas-AAPS-2022-PharmSci-360-Accepts-Abstract-for-ADRULIPASE-Formulation.gif)
Breaking News: First Wave Biopharma’s AAPS 2022 PharmSci 360 Accepts Abstract for ADRULIPASE Formulation!
First Wave BioPharma Announces Exciting Development in Formulation of Microgranule Delivery for Adrulipase The Breakthrough Announcement BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that…